Mylan Recalls Tacrolimus Capsules Due to Potential Foreign Capsule Presence
Mylan Pharmaceuticals is recalling specific lots of 5mg Tacrolimus capsules because 1mg capsules may be present in the bottles.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class III recall, which indicates a low probability of adverse health consequences. The hazard involves a potential dosage error due to a foreign capsule, which is a significant quality issue but does not meet the criteria for higher severity scores without reported injuries.
Plain-English summary
Mylan Pharmaceuticals Inc. is recalling 3,816 bottles of Tacrolimus Capsules, USP 5mg, 100-count. The recall involves Lot # 3105410 and 3106268, with an expiration date of 9/2020. The product is distributed nationwide in the U.S.A.
The recall was initiated due to the potential presence of a foreign tablet or capsule. Specifically, there is a risk that one 1 mg Tacrolimus capsule may be commingled in the 5 mg bottles. This discrepancy could result in patients receiving an incorrect dosage of the medication.
Consumers who have these specific lot numbers should stop using the product and contact their healthcare provider or pharmacist for guidance. The affected product is a prescription-only oral medication manufactured by Mylan Pharmaceuticals Inc. in Morgantown, WV.
The recalled product
- Product
- TACROLIMUS (TACROLIMUS)
- Brand
- TACROLIMUS
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 3,816
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # 3105410
- 3106268
- Exp 9/2020
UPCs (3)
- 0303782046014
- 0303782045017
- 0303782047011
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TACROLIMUS
- HighPrescription Tacrolimus Capsules Recalled for Wrong-Strength Product Mix
FDA (Drugs) · 2024-01-17
- HighTacrolimus Capsules Recalled for Wrong-Strength Tablets Co-Mingled in Bottles
FDA (Drugs) · 2023-03-01
- LowTacrolimus Ointment Recalled for Defective Containers That Split
FDA (Drugs) · 2022-08-10
- LowStrides Pharma Recalls Tacrolimus Capsules for Failed Moisture Limits
FDA (Drugs) · 2021-01-06
- SevereSandoz Recalls Tacrolimus Capsules Due to Fluvastatin Cross-Contamination
FDA (Drugs) · 2014-01-01
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · foreign object
See all →- SevereOutshine Strawberry Fruit Bars Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02
- SevereOutshine Black Cherry Fruit Bars Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02
- SevereOutshine Fruit Bars Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02
- SevereOutshine Fruit Bars Grape Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02
- SevereOutshine Watermelon Fruit Bars Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02